Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Neurogene (NGNE) over the last 13 years, with Dec 2024 value amounting to -$2.8 million.

  • Neurogene's Change in Accured Expenses fell 86.18% to $365,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$409,000, marking a year-over-year increase of 92.81%. This contributed to the annual value of -$2.8 million for FY2024, which is 22.41% up from last year.
  • Neurogene's Change in Accured Expenses amounted to -$2.8 million in FY2024, which was up 22.41% from -$3.6 million recorded in FY2023.
  • In the past 5 years, Neurogene's Change in Accured Expenses ranged from a high of $3.0 million in FY2020 and a low of -$3.6 million during FY2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$2.8 million (2024), whereas its average is -$1.8 million.
  • Per our database at Business Quant, Neurogene's Change in Accured Expenses spiked by 667.61% in 2022 and then plummeted by 543.42% in 2023.
  • Yearly analysis of 5 years shows Neurogene's Change in Accured Expenses stood at $3.0 million in 2020, then tumbled by 104.71% to -$142,000 in 2021, then surged by 667.61% to $806,000 in 2022, then tumbled by 543.42% to -$3.6 million in 2023, then climbed by 22.41% to -$2.8 million in 2024.